Corrigendum to ‘The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer’ :  [ESMO Open Volume 6, Issue 2, April 2021, 100078]

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Related collections

Author and article information

Contributors

A. Cortellini

Journal

Journal ID (nlm-ta): ESMO Open

Journal ID (iso-abbrev): ESMO Open

Title: ESMO Open

Publisher: Elsevier

ISSN (Electronic): 2059-7029

Publication date PMC-release: 03 June 2021

Publication date Collection: June 2021

Publication date (Electronic): 03 June 2021

Volume: 6

Issue: 3

Electronic Location Identifier: 100137

Affiliations

[1 ]Oncology Department, Portsmouth University Hospitals NHS Trust, Portsmouth, UK

[2 ]Department of Surgery and Cancer, Imperial College London, London, UK

[3 ]Department of Biotechnology and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy

[4 ]Medical Oncology, Ospedale San Gerardo, Monza, Italy

[5 ]Medical Oncology Unit, University Hospital of Parma, Parma, Italy

[6 ]Department of Medicine and Surgery, University of Parma, Parma, Italy

[7 ]Department of Pulmonary Diseases, Erasmus Medical Center, Rotterdam, the Netherlands

[8 ]Department of Oncology and Hematology, Modena University Hospital, Modena, Italy

[9 ]Medical Oncology, St. Andrea Hospital, Rome, Italy

[10 ]Comprehensive Cancer Center, Fondazione Policlinico Universitario ‘A. Gemelli’ IRCCS, Rome, Italy

[11 ]Department of Translational Medicine and Surgery, Università Cattolica del Sacro Cuore, Rome, Italy

[12 ]Medical Oncology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy

[13 ]Thoracic Oncology Unit, Clinical Cancer Center IRCCS Istituto Tumori ‘Giovanni Paolo II’, Bari, Italy

[14 ]Oncology Clinic, Università Politecnica Delle Marche, Ospedali Riuniti Di Ancona, Ancona, Italy

[15 ]Thoracic Medical Oncology, Istituto Nazionale Tumori ‘Fondazione G Pascale’, IRCCS, Napoli, Italy

[16 ]Lung Cancer Unit, IRCCS Ospedale Policlinico San Martino, Genova, Italy

[17 ]Department of Oncology, Careggi University Hospital, Florence, Italy

[18 ]Medical Oncology, University Hospital of Foggia, Foggia, Italy

[19 ]Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

[20 ]Medical Oncology (B), Policlinico Umberto I, ‘Sapienza’ University of Rome, Rome, Italy

[21 ]Department of Oncology, University Hospital Santa Maria Della Misericordia, Udine, Italy

[22 ]Medical Oncology, Fermo Area Vasta 4, Fermo, Italy

[23 ]Medical Oncology, Ospedali Riuniti Padova Sud ‘Madre Teresa Di Calcutta’, Monselice, Italy

[24 ]Pneumo-Oncology Unit, Monaldi Hospital, Naples, Italy

[25 ]Oncology Unit, IRCCS Ospedale Sacro Cuore Don Calabria, Negrar di Valpolicella VR, Italy

[26 ]Department of Medical, Oral & Biotechnological Sciences University G. D'Annunzio, Chieti-Pescara, Chieti, Italy

[27 ]Clinical Oncology Unit, S.S. Annunziata Hospital, Chieti, Italy

[28 ]Medical Oncology, F. Spaziani Hospital, Frosinone, Italy

[29 ]Medical Oncology, Santa Maria Goretti Hospital, Latina, Italy

[30 ]Medical Oncology, Campus Bio-Medico University, Rome, Italy

[31 ]Medical Oncology, ASST-Sette Laghi, Varese, Italy

[32 ]Department of Oncology and Hematology, AUSL Romagna, Ravenna, Italy

[33 ]Medical Oncology Unit, University Hospital and University of Cagliari, Cagliari, Italy

[34 ]Oncology Department, University Hospital of Geneva, Geneva, Switzerland

[35 ]Division of Medical Oncology, S.Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy

[36 ]Department of Medical Oncology, Santa Maria della Misericordia Hospital, Azienda Ospedaliera di Perugia, Perugia, Italy

[37 ]Medical Oncology, St. Salvatore Hospital, L'Aquila, Italy

Author notes

[∗ ] Correspondence to: A. Cortellini. a.cortellini@ 123456imperial.ac.uk alessiocortellini@ 123456gmail.com

Article

Publisher Item ID: S2059-7029(21)00096-X Publisher ID: 100137

DOI: 10.1016/j.esmoop.2021.100137

PMC ID: 8233644

PubMed ID: 34144775

SO-VID: 44b7438d-5c4d-40b2-98e7-11460db078a0

License:

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Corrigendum to ‘The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer’ : [ESMO Open Volume 6, Issue 2, April 2021, 100078]

Read this article at

Related collections

Inflamed lung in vitro co-culture models

Author and article information

Contributors

Journal

Affiliations

Author notes

Article

History

Categories

Comments

Comment on this article

Similar content 697

Cited by 3